{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:09Z","timestamp":1787729409069,"version":"build-2784847793"},"reference-count":49,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"DOI":"10.20945\/2359-4292-2024-0035","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:33:30Z","timestamp":1729528410000},"source":"Crossref","is-referenced-by-count":8,"title":["Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5838-0931","authenticated-orcid":false,"given":"Lisa","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-689X","authenticated-orcid":false,"given":"Verena","family":"Theiler-Schwetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1767-555X","authenticated-orcid":false,"given":"Patrick","family":"Sadoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-4554","authenticated-orcid":false,"given":"Christian","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-1311","authenticated-orcid":false,"given":"Stefan","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"5","key":"key20241021163323_B1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","unstructured":"1 Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401-19. doi: 10.1038\/nrd3705.","journal-title":"Nat Rev Drug Discov."},{"issue":"8","key":"key20241021163323_B2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","unstructured":"2 Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65. doi: 10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med."},{"key":"key20241021163323_B3","doi-asserted-by":"crossref","first-page":"h2723","DOI":"10.1136\/bmj.h2723","article-title":"The diagnosis and management of hypercalcaemia","volume":"350","author":"Minisola","year":"2015","unstructured":"3 Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723. doi: 10.1136\/bmj.h2723.","journal-title":"BMJ"},{"issue":"3","key":"key20241021163323_B4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7861\/clinmedicine.17-3-270","article-title":"Hypercalcaemia - presentation and management","volume":"17","author":"Turner","year":"2017","unstructured":"4 Turner JJO. Hypercalcaemia - presentation and management. Clin Med (Lond). 2017;17(3):270-3. doi: 10.7861\/clinmedicine.17-3-270.","journal-title":"Clin Med (Lond)."},{"issue":"4","key":"key20241021163323_B5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ecl.2021.08.001","article-title":"Drug-Related Hypercalcemia","volume":"50","author":"Lecoq","year":"2021","unstructured":"5 Lecoq AL, Livrozet M, Blanchard A, Kamenick\u00fd P. Drug-Related Hypercalcemia. Endocrinol Metab Clin North Am. 2021;50(4):743-52. doi: 10.1016\/j.ecl.2021.08.001.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"key20241021163323_B6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review","volume":"10","author":"Anastasilakis","year":"2021","unstructured":"6 Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A. Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. J Clin Med. 2021;10(1):152. doi: 10.3390\/jcm10010152.","journal-title":"J Clin Med"},{"issue":"11","key":"key20241021163323_B7","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s00198-021-06002-5","article-title":"Denosumab for the treatment of primary pediatric osteoporosis","volume":"32","author":"Anastasilakis","year":"2021","unstructured":"7 Anastasilakis AD, Makras P, Doulgeraki A, Polyzos SA, Guarnieri V, Papapoulos SE. Denosumab for the treatment of primary pediatric osteoporosis. Osteoporos Int. 2021;32(11):2377-81. doi: 10.1007\/s00198-021-06002-5.","journal-title":"Osteoporos Int."},{"issue":"7","key":"key20241021163323_B8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","unstructured":"8 Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462-70. doi: 10.1002\/jbmr.1603.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"key20241021163323_B9","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00198-020-05676-7","article-title":"Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review","volume":"31","author":"Camponovo","year":"2020","unstructured":"9 Camponovo C, Aubry-Rozier B, Lamy O, Gonzalez Rodriguez E. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int. 2020;31(12):2485-91. doi: 10.1007\/s00198-020-05676-7.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20241021163323_B10","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28778","article-title":"Treatment of central giant cell granuloma in children with denosumab","volume":"68","author":"Choe","year":"2021","unstructured":"10 Choe M, Smith V, Okcu MF, Wulff J, Gruner S, Huisman T, et al. Treatment of central giant cell granuloma in children with denosumab. Pediatr Blood Cancer. 2021;68(3):e28778. doi: 10.1002\/pbc.28778.","journal-title":"Pediatr Blood Cancer."},{"key":"key20241021163323_B11","doi-asserted-by":"crossref","first-page":"698963","DOI":"10.3389\/fendo.2021.698963","article-title":"Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report","volume":"12","author":"Del Sindaco","year":"2021","unstructured":"11 Del Sindaco G, Berlanga P, Brugi\u00e8res L, Thebault E, Mantovani G, Wicart P, et al. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Front Endocrinol (Lausanne). 2021;12:698963. doi: 10.3389\/fendo.2021.698963.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"key20241021163323_B12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40618-021-01630-4","article-title":"Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab","volume":"45","author":"Deodati","year":"2022","unstructured":"12 Deodati A, Fintini D, Levtchenko E, Rossi M, Ubertini G, Segers H, et al. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab. J Endocrinol Invest. 2022;45(1):159-66. doi: 10.1007\/s40618-021-01630-4.","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"key20241021163323_B13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12891-019-2855-y","article-title":"Aneurysmal bone cyst: results of an off label treatment with Denosumab","volume":"20","author":"D\u00fcrr","year":"2019","unstructured":"13 D\u00fcrr HR, Grahneis F, Baur-Melnyk A, Kn\u00f6sel T, Birkenmaier C, Jansson V, et al. Aneurysmal bone cyst: results of an off label treatment with Denosumab. BMC Musculoskelet Disord. 2019;20(1):456. doi: 10.1186\/s12891-019-2855-y.","journal-title":"BMC Musculoskelet Disord."},{"key":"key20241021163323_B14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fped.2020.00515","article-title":"Case Report: Safety and Efficacy of Denosumab in Four Children with Noonan Syndrome with Multiple Giant Cell Lesions of the Jaw","volume":"8","author":"Ferriero","year":"2020","unstructured":"14 Ferriero K, Shah B, Yan Y, Khatri S, Caccamese J, Napoli JA, et al. Case Report: Safety and Efficacy of Denosumab in Four Children with Noonan Syndrome with Multiple Giant Cell Lesions of the Jaw. Front Pediatr. 2020;8:515. doi: 10.3389\/fped.2020.00515.","journal-title":"Front Pediatr."},{"issue":"6","key":"key20241021163323_B15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","unstructured":"15 Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078-80. doi: 10.1002\/pbc.25393.","journal-title":"Pediatr Blood Cancer."},{"issue":"8","key":"key20241021163323_B16","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease","volume":"98","author":"Grasemann","year":"2013","unstructured":"16 Grasemann C, Sch\u00fcndeln MM, H\u00f6vel M, Schweiger B, Bergmann C, Herrmann R, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. J Clin Endocrinol Metab. 2013;98(8):3121-6. doi: 10.1210\/jc.2013-1143.","journal-title":"J Clin Endocrinol Metab."},{"key":"key20241021163323_B17","first-page":"8854441","article-title":"The Efficacy of Denosumab in the Management of a Tibial Paediatric Aneurysmal Bone Cyst Compromised by Rebound Hypercalcaemia","volume":"2020","author":"Harcus","year":"2020","unstructured":"17 Harcus M, Aldridge S, Abudu A, Jeys L, Senniappan S, Morgan H, et al. The Efficacy of Denosumab in the Management of a Tibial Paediatric Aneurysmal Bone Cyst Compromised by Rebound Hypercalcaemia. Case Rep Pediatr. 2020;2020:8854441. doi: 10.1155\/2020\/8854441.","journal-title":"Case Rep Pediatr."},{"key":"key20241021163323_B18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00586-018-5651-8","article-title":"Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child: case report and literature review","volume":"27","author":"Irmola","year":"2018","unstructured":"18 Irmola T, Laitinen MK, Parkkinen J, Engellau J, Neva MH. Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child: case report and literature review. Eur Spine J. 2018;27(Suppl 3):555-60. doi: 10.1007\/s00586-018-5651-8.","journal-title":"Eur Spine J."},{"issue":"7","key":"key20241021163323_B19","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1515\/jpem-2019-0581","article-title":"Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism","volume":"33","author":"Kawamura","year":"2020","unstructured":"19 Kawamura H, Watanabe S, I T, Asahina I, Moriuchi H, Dateki S. Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism. J Pediatr Endocrinol Metab. 2020;33(7):963-6. doi: 10.1515\/jpem-2019-0581.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"key20241021163323_B20","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","article-title":"Hypercalcemia after discontinuation of long-term denosumab treatment","volume":"27","author":"Koldkj\u00e6r S\u00f8lling","year":"2016","unstructured":"20 Koldkj\u00e6r S\u00f8lling AS, Harsl\u00f8f T, Kaal A, Rejnmark L, Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int. 2016;27(7):2383-6. doi: 10.1007\/s00198-016-3535-5.","journal-title":"Osteoporos Int"},{"issue":"4","key":"key20241021163323_B21","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26926","article-title":"Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases","volume":"65","author":"Kurucu","year":"2018","unstructured":"21 Kurucu N, Akyuz C, Ergen FB, Yalcin B, Kosemehmetoglu K, Ayvaz M, et al. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases. Pediatr Blood Cancer. 2018;65(4). doi: 10.1002\/pbc.26926.","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"key20241021163323_B22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/scd.12588","article-title":"Successful denosumab treatment for central giant cell granuloma in a 9-year-old child","volume":"41","author":"Mariz","year":"2021","unstructured":"22 Mariz B, Migliorati CA, Alves FA, Penteado FM, Carvalho NPF, Santos-Silva AR, et al. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. Spec Care Dentist. 2021;41(4):519-25. doi: 10.1111\/scd.12588.","journal-title":"Spec Care Dentist."},{"issue":"1","key":"key20241021163323_B23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13256-020-02401-0","article-title":"Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report","volume":"14","author":"Maugars","year":"2020","unstructured":"23 Maugars Y, Guillot P, Gl\u00e9marec J, Berthelot JM, Le Goff B, Darrieutort-Laffite C. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report. J Med Case Rep. 2020;14(1):130. doi: 10.1186\/s13256-020-02401-0.","journal-title":"J Med Case Rep"},{"issue":"9","key":"key20241021163323_B24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.4380","article-title":"Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study","volume":"36","author":"Meier","year":"2021","unstructured":"24 Meier ME, Clerkx SN, Winter EM, Pereira AM, van de Ven AC, van de Sande MAJ, et al. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res. 2021;36(9):1729-38. doi: 10.1002\/jbmr.4380.","journal-title":"J Bone Miner Res."},{"issue":"12","key":"key20241021163323_B25","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.joms.2014.06.456","article-title":"Management of central giant cell granuloma with subcutaneous denosumab therapy","volume":"72","author":"Naidu","year":"2014","unstructured":"25 Naidu A, Malmquist MP, Denham CA, Schow SR. Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg. 2014;72(12):2469-84. doi: 10.1016\/j.joms.2014.06.456.","journal-title":"J Oral Maxillofac Surg."},{"issue":"9","key":"key20241021163323_B26","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00198-021-05895-6","article-title":"Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects","volume":"32","author":"Raborn","year":"2021","unstructured":"26 Raborn LN, Burke AB, Ebb DH, Collins MT, Kaban LB, Boyce AM. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int. 2021;32(9):1889-93. doi: 10.1007\/s00198-021-05895-6.","journal-title":"Osteoporos Int."},{"issue":"6","key":"key20241021163323_B27","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.otsr.2019.04.028","article-title":"Denosumab for treating aneurysmal bone cysts in children","volume":"105","author":"Raux","year":"2019","unstructured":"27 Raux S, Bouhamama A, Gaspar N, Brugi\u00e8res L, Entz-Werl\u00e9 N, Mallet C, et al. Denosumab for treating aneurysmal bone cysts in children. Orthop Traumatol Surg Res. 2019;105(6):1181-5. doi: 10.1016\/j.otsr.2019.04.028.","journal-title":"Orthop Traumatol Surg Res."},{"issue":"4","key":"key20241021163323_B28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00223-021-00935-z","article-title":"Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study","volume":"110","author":"Rhou","year":"2022","unstructured":"28 Rhou YJJ, Wang CJ, Nguyen M, Vanderniet JA, Munns CF, Coleman H, et al. Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study. Calcif Tissue Int. 2022;110(4):464-74. doi: 10.1007\/s00223-021-00935-z.","journal-title":"Calcif Tissue Int."},{"key":"key20241021163323_B29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2018.12.012","article-title":"Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review","volume":"120","author":"Roux","year":"2019","unstructured":"29 Roux S, Massicotte MH, Huot Daneault A, Brazeau-Lamontagne L, Dufresne J. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. Bone. 2019;120:482-6. doi: 10.1016\/j.bone.2018.12.012.","journal-title":"Bone"},{"issue":"1","key":"key20241021163323_B30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","unstructured":"30 Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A, et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2016;34(1):118-22. doi: 10.1007\/s00774-015-0677-z.","journal-title":"J Bone Miner Metab."},{"issue":"5","key":"key20241021163323_B31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12519-020-00378-w","article-title":"Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?","volume":"16","author":"Sydlik","year":"2020","unstructured":"31 Sydlik C, D\u00fcrr HR, Pozza SB, Wei\u00dfenbacher C, Roeb J, Schmidt H. Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention? World J Pediatr. 2020;16(5):520-7. doi: 10.1007\/s12519-020-00378-w.","journal-title":"World J Pediatr"},{"issue":"1","key":"key20241021163323_B32","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","unstructured":"32 Trejo P, Rauch F, Ward L. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2018;18(1):76-80.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"key20241021163323_B33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1507\/endocrj.EJ19-0198","article-title":"Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab","volume":"67","author":"Uchida","year":"2020","unstructured":"33 Uchida T, Yamaguchi H, Kushima C, Yonekawa T, Nakazato M. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab. Endocr J. 2020;67(1):31-5. doi: 10.1507\/endocrj.EJ19-0198.","journal-title":"Endocr J"},{"issue":"2","key":"key20241021163323_B34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone","volume":"103","author":"Uday","year":"2018","unstructured":"34 Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, et al. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. J Clin Endocrinol Metab. 2018;103(2):596-603. doi: 10.1210\/jc.2017-02025.","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"key20241021163323_B35","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10210","article-title":"Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases","volume":"3","author":"Upfill-Brown","year":"2019","unstructured":"35 Upfill-Brown A, Bukata S, Bernthal NM, Felsenfeld AL, Nelson SD, Singh A, et al. Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases. JBMR Plus. 2019;3(10):e10210. doi: 10.1002\/jbm4.10210.","journal-title":"JBMR Plus."},{"issue":"5","key":"key20241021163323_B36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-023-01068-1","article-title":"Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre","volume":"112","author":"Vanderniet","year":"2023","unstructured":"36 Vanderniet JA, Tsinas D, Wall CL, Girgis CM, London K, Keane C, et al. Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre. Calcif Tissue Int. 2023;112(5):592-602. doi: 10.1007\/s00223-023-01068-1.","journal-title":"Calcif Tissue Int."},{"key":"key20241021163323_B37","doi-asserted-by":"crossref","first-page":"116395","DOI":"10.1016\/j.bone.2022.116395","article-title":"Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre","volume":"159","author":"Vanderniet","year":"2022","unstructured":"37 Vanderniet JA, Wall CL, Mullins A, London K, Lim L, Hibbert S, et al. Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre. Bone. 2022;159:116395. doi: 10.1016\/j.bone.2022.116395.","journal-title":"Bone."},{"issue":"7","key":"key20241021163323_B38","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-022-06369-z","article-title":"Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer","volume":"33","author":"Wang","year":"2022","unstructured":"38 Wang R, Renouf DA. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer. Osteoporos Int. 2022;33(7):1625-9. doi: 10.1007\/s00198-022-06369-z.","journal-title":"Osteoporos Int."},{"issue":"4","key":"key20241021163323_B39","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0287","article-title":"Diagnosis and management of parathyroid carcinoma: a state-of-the-art review","volume":"30","author":"Roser","year":"2023","unstructured":"39 Roser P, Leca BM, Coelho C, Schulte KM, Gilbert J, Drakou EE, et al. Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocr Relat Cancer. 2023;30(4):e220287. doi: 10.1530\/ERC-22-0287.","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"key20241021163323_B40","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-19-0316","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders","volume":"181","author":"Bollerslev","year":"2019","unstructured":"40 Bollerslev J, Schalin-J\u00e4ntti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R, et al. MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019;181(3):P1-P19. doi: 10.1530\/EJE-19-0316.","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"key20241021163323_B41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-011-0171-3","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","author":"Wei","year":"2012","unstructured":"41 Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13(1):11-23. doi: 10.1007\/s11864-011-0171-3.","journal-title":"Curr Treat Options Oncol."},{"issue":"10","key":"key20241021163323_B42","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrendo.2012.102","article-title":"Diagnosis and management of parathyroid cancer","volume":"8","author":"Schulte","year":"2012","unstructured":"42 Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8(10):612-22. doi: 10.1038\/nrendo.2012.102.","journal-title":"Nat Rev Endocrinol."},{"issue":"2","key":"key20241021163323_B43","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders","volume":"186","author":"Bollerslev","year":"2022","unstructured":"43 Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, et al. European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2022;186(2):R33-R63. doi: 10.1530\/EJE-21-1044.","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"key20241021163323_B44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an Emerging Therapy in Pediatric Bone Disorders","volume":"15","author":"Boyce","year":"2017","unstructured":"44 Boyce AM. Denosumab: an Emerging Therapy in Pediatric Bone Disorders. Curr Osteoporos Rep. 2017;15(4):283-92. doi: 10.1007\/s11914-017-0380-1.","journal-title":"Curr Osteoporos Rep."},{"issue":"16","key":"key20241021163323_B45","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: A Review","volume":"328","author":"Walker","year":"2022","unstructured":"45 Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022;328(16):1624-36. doi: 10.1001\/jama.2022.18331.","journal-title":"JAMA."},{"issue":"3","key":"key20241021163323_B46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","unstructured":"46 El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, et al. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507-28. doi: 10.1210\/clinem\/dgac621.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"key20241021163323_B47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00431-022-04743-x","article-title":"Osteoporosis in children and adolescents: how to treat and monitor?","volume":"182","author":"Ciancia","year":"2023","unstructured":"47 Ciancia S, H\u00f6gler W, Sakkers RJB, Appelman-Dijkstra NM, Boot AM, Sas TCJ, et al. Osteoporosis in children and adolescents: how to treat and monitor? Eur J Pediatr. 2023;182(2):501-11. doi: 10.1007\/s00431-022-04743-x.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"key20241021163323_B48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping Denosumab","volume":"17","author":"Lamy","year":"2019","unstructured":"48 Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr Osteoporos Rep. 2019;17(1):8-15. doi: 10.1007\/s11914-019-00502-4.","journal-title":"Curr Osteoporos Rep."},{"issue":"1","key":"key20241021163323_B49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab Discontinuation","volume":"21","author":"S\u00f8lling","year":"2023","unstructured":"49 S\u00f8lling AS, Tsourdi E, Harsl\u00f8f T, Langdahl BL. Denosumab Discontinuation. Curr Osteoporos Rep. 2023;21(1):95-103.","journal-title":"Curr Osteoporos Rep."}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:33:40Z","timestamp":1729528420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/rebound-hypercalcemia-after-denosumab-cessation-during-follow-up-after-surgical-treatment-for-parathyroid-carcinoma-case-report-and-literature-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":49,"alternative-id":["10.20945\/2359-4292-2024-0035"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2024-0035","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e240035"}}